JP2024520756A5 - - Google Patents

Info

Publication number
JP2024520756A5
JP2024520756A5 JP2023575397A JP2023575397A JP2024520756A5 JP 2024520756 A5 JP2024520756 A5 JP 2024520756A5 JP 2023575397 A JP2023575397 A JP 2023575397A JP 2023575397 A JP2023575397 A JP 2023575397A JP 2024520756 A5 JP2024520756 A5 JP 2024520756A5
Authority
JP
Japan
Prior art keywords
peg
pharmaceutical composition
composition according
polypeptide
lnp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520756A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/032510 external-priority patent/WO2022261101A1/en
Publication of JP2024520756A publication Critical patent/JP2024520756A/ja
Publication of JP2024520756A5 publication Critical patent/JP2024520756A5/ja
Pending legal-status Critical Current

Links

JP2023575397A 2021-06-07 2022-06-07 ApoE及びApoB修飾脂質ナノ粒子組成物及びその使用 Pending JP2024520756A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163197881P 2021-06-07 2021-06-07
US63/197,881 2021-06-07
PCT/US2022/032510 WO2022261101A1 (en) 2021-06-07 2022-06-07 Apoe and apob modified lipid nanoparticle compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2024520756A JP2024520756A (ja) 2024-05-24
JP2024520756A5 true JP2024520756A5 (cg-RX-API-DMAC7.html) 2025-06-17

Family

ID=84426303

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575397A Pending JP2024520756A (ja) 2021-06-07 2022-06-07 ApoE及びApoB修飾脂質ナノ粒子組成物及びその使用

Country Status (9)

Country Link
US (1) US20240299580A1 (cg-RX-API-DMAC7.html)
EP (1) EP4351533A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024520756A (cg-RX-API-DMAC7.html)
KR (1) KR20240019244A (cg-RX-API-DMAC7.html)
CN (1) CN117897143A (cg-RX-API-DMAC7.html)
AU (1) AU2022288618A1 (cg-RX-API-DMAC7.html)
CA (1) CA3221454A1 (cg-RX-API-DMAC7.html)
IL (1) IL308928A (cg-RX-API-DMAC7.html)
WO (1) WO2022261101A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4626402A1 (en) 2022-12-01 2025-10-08 Generation Bio Co. Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
US20260207525A1 (en) 2022-12-01 2026-07-23 Generation Bio Co. Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
JP2025541726A (ja) 2022-12-01 2025-12-23 ジェネレーション バイオ カンパニー 細胞標的化のためのステルス脂質ナノ粒子組成物
AU2023406321A1 (en) 2022-12-01 2025-05-29 Generation Bio Co. Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
EP4648754A1 (en) * 2023-01-09 2025-11-19 Northmirs, Inc. Microrna-based particle for the treatment of dysregulated immune response
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
JP2026512425A (ja) 2023-03-30 2026-04-16 オーエスイー・イミュノセラピューティクス 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
EP4704855A1 (en) * 2023-04-26 2026-03-11 Saliogen Therapeutics, Inc. Lipid nanoparticle (lnp) formulations
IT202300015291A1 (it) * 2023-07-20 2025-01-20 Fond Riccardo Terzi E Silvio Albini Sistema di rilascio comprendente nanoparticelle lipidiche o polimeriche comprendenti ormoni tiroidei
WO2025052180A2 (en) 2023-09-07 2025-03-13 Axelyf ehf. Lipids and lipid nanoparticles
WO2025230906A1 (en) * 2024-04-29 2025-11-06 Saliogen Therapeutics, Inc. Lipid nanoparticle (lnp) formulations
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
CN118453517B (zh) * 2024-07-15 2024-10-08 杭州珞米医疗科技有限公司 一种靶向结合ldlr的组合物及其应用
WO2026052871A1 (en) * 2024-09-09 2026-03-12 Re3B Therapeutics Ug (I.G.) Serum-protein coated fusogenic lipid particles for targeted drug delivery
WO2026064512A1 (en) 2024-09-18 2026-03-26 Generation Bio Co. Polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029125A2 (en) * 2004-09-07 2006-03-16 Kos Life Sciences, Inc. Methods and compositions for treating hypercholesterolemia
US20090131358A1 (en) * 2007-11-15 2009-05-21 Alcon Research, Ltd. LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
EP3672602A1 (en) * 2017-08-22 2020-07-01 Rubius Therapeutics, Inc. Lipid nanoparticle methods and compositions for producing engineered erythroid cells
AU2020232790A1 (en) * 2019-03-06 2021-09-16 Generation Bio Co. Non-active lipid nanoparticles with non-viral, capsid free DNA
CN114929205B (zh) * 2019-09-06 2024-09-03 世代生物公司 包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法
US20230365995A1 (en) * 2020-10-07 2023-11-16 Precision Biosciences, Inc. Lipid nanoparticle compositions

Similar Documents

Publication Publication Date Title
Sun et al. Structure and function of cationic and ionizable lipids for nucleic acid delivery
US12252470B2 (en) Lipids and nanoparticle compositions thereof
JP2023534043A5 (cg-RX-API-DMAC7.html)
AU2020423601B2 (en) Lipid nanoparticles for in-vivo drug delivery, and uses thereof
US20230320993A1 (en) Methods for encapsulating polynucleotides into reduced sizes of lipid nanoparticles and novel formulation thereof
US20220370357A1 (en) Ionizable lipids and nanoparticle compositions thereof
US12263228B2 (en) Lipids and compositions thereof
JP2024520756A (ja) ApoE及びApoB修飾脂質ナノ粒子組成物及びその使用
US20240293574A1 (en) Cationic lipids and compositions thereof
JP2011529912A (ja) 核酸送達システム用のナノ粒子組成物
JP2024517644A5 (cg-RX-API-DMAC7.html)
JP2024522692A5 (cg-RX-API-DMAC7.html)
US20230181764A1 (en) Novel lipids and nanoparticle compositions thereof
JP2024529343A5 (cg-RX-API-DMAC7.html)
JP2025541727A (ja) 新規のポリグリセロールコンジュゲート脂質及びそれを含む脂質ナノ粒子組成物
Koynova et al. Recent patents in cationic lipid carriers for delivery of nucleic acids
Sorgi et al. Drug delivery applications
KR20250158420A (ko) 신규 이온화지질 및 이를 포함하는 지질나노입자
NICOLAUª et al. ªCBR Laboratories and Harvard Medical School, Boston, MA 02135, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA and CPMCRI, San Francisco, CA 94115, USA
BHATTACHARYAT et al. Cationic liposome-DNA complexes in